Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides [Yahoo! ...
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
United States-based Apostolos Klontzaris appointed Chief Business Officer (CBO) to drive development and expand footprint in North America and Europe, bringing experience at major crop science companies Bayer and Syngenta, as well as Oerth Bio and Flagship Pioneering Moa is developing next-generation herbicides with novel modes of action (MOAs) to tackle the growing crisis in agriculture caused by herbicide-resistant weeds amid climate change and population growth Spun out of the University of Oxford, and backed by leading venture investors, Moa uses unique plant-centric platforms together with innovations employed in health-focused biotech to identify, understand and develop new herbicides with game-changing speed and accuracy OXFORD, United Kingdom, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Moa Technology (Moa or the Company), the agricultural biotechnology (agribio) company tackling herbicide-resistant weeds that threaten the world's food security, today announces the appointment of
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - TechnavioPR Newswire
- Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]Seeking Alpha
- Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- Silence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesBusiness Wire
SLN
Sec Filings
- 8/15/24 - Form 6-K
- 8/2/24 - Form SC
- SLN's page on the SEC website